773848-51-4 Usage
General Description
1-[(1R)-Phenylethyl]piperazine, also known as PEP, is a chemical compound with the molecular formula C11H16N2. It is a piperazine derivative that is commonly used in the synthesis of pharmaceuticals and various drugs. PEP has been identified as an inhibitor of monoamine oxidase (MAO), a family of enzymes that catalyze the oxidation of monoamines, which can lead to the breakdown of neurotransmitters such as serotonin, dopamine, and norepinephrine. PEP has also been studied for its potential use as a potential treatment for conditions such as depression and anxiety disorders, due to its ability to modulate neurotransmitter levels in the brain. Additionally, PEP has been investigated for its potential anti-inflammatory and antiviral properties, making it a compound of interest in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 773848-51-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,3,8,4 and 8 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 773848-51:
(8*7)+(7*7)+(6*3)+(5*8)+(4*4)+(3*8)+(2*5)+(1*1)=214
214 % 10 = 4
So 773848-51-4 is a valid CAS Registry Number.
InChI:InChI=1/C12H18N2/c1-11(12-5-3-2-4-6-12)14-9-7-13-8-10-14/h2-6,11,13H,7-10H2,1H3/t11-/m1/s1
773848-51-4Relevant articles and documents
Synthesis of Enantiopure Piperazines via Asymmetric Lithiation-Trapping of N-Boc Piperazines: Unexpected Role of the Electrophile and Distal N-Substituent
Firth, James D.,O'Brien, Peter,Ferris, Leigh
, p. 651 - 659 (2016/01/29)
A new method for the synthesis of enantiopure α-substituted piperazines via direct functionalization of the intact piperazine ring is described. The approach utilizes the asymmetric lithiation-substitution of an α-methylbenzyl-functionalized N-Boc piperaz
UROTENSIN II RECEPTOR ANTAGONISTS
-
Page/Page column 197-198, (2010/11/28)
The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
